Allogeneic therapies, specifically CD19-CAR-specific transfers, can render objective responses in 83% of patients with acute lymphoblast leukemia (ALL) [5,10,11] and 27% of patients with chronic lymphoblastic leukemia (CLL) [12–14]. Here, CD19 is linked to acute lymphoblastic leukemia.